-
Product Insights
Voltalia LCL solar PV Park
Voltalia LCL solar PV Park is a solar PV project located in France. The project is owned and being developed by Voltalia SA. The project is at the permitting stage. Empower your strategies with our Voltalia LCL solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LCL-161 in Myelofibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LCL-161 in Myelofibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.LCL-161 in Myelofibrosis Drug Details:LCL-161 is under development for the treatment of primary myelofibrosis,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tavo-101 in Allergies
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tavo-101 in Allergies report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tavo-101 in Allergies Drug Details: Tavo-101 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LCL-161 in Post-Polycythemia Vera Myelofibrosis (PPV-MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LCL-161 in Post-Polycythemia Vera Myelofibrosis (PPV-MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.LCL-161 in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Drug Details:LCL-161 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LCL-161 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LCL-161 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.LCL-161 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug Details:LCL-161 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MHB-088C in Thyroid Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MHB-088C in Thyroid Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MHB-088C in Thyroid Cancer Drug Details: MHB-088C is under development for...
-
Company Insights
Atos SE – Digital Transformation Strategies
Atos Digital Transformation Strategies Overview Atos SE (Atos) is tapping into the power of key disruptive technologies to offer new products/services and achieve operational efficiency. AI, big data, cloud, cybersecurity, and IoT are among the key technologies under focus for the company. The annual ICT spending of Atos is estimated at $725.5 million for 2023. A major share of this spending is earmarked for acquiring software, ICT services, and hardware from vendors. Atos is a French IT company. It offers...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ZND-5 in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ZND-5 in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ZND-5 in Peripheral T-Cell Lymphomas (PTCL) Drug Details: ZNd-5...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ZND-5 in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ZND-5 in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ZND-5 in Non-Hodgkin Lymphoma Drug Details: ZNd-5 is under development for...